ProCE Banner Activity

BILCAP: Phase III Trial of Adjuvant Capecitabine for Biliary Tract Cancer

Slideset Download
Conference Coverage
In this trial, adjuvant capecitabine improved survival vs placebo in patients with resected biliary cancer with modest toxicity and no reduction in quality of life.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology